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Background: Thymomas are one of the most rarely diagnosed malignancies. To better understand its biology and to identify
therapeutic targets, we performed next-generation RNA sequencing.
Methods: The RNA was sequenced from 13 thymic malignancies and 3 normal thymus glands. Validation of microRNA expression
was performed on a separate set of 35 thymic malignancies. For cell-based studies, a thymoma cell line was used.
Results: Hierarchical clustering revealed 100% concordance between gene expression clusters and WHO subtype. A substantial
differentiator was a large microRNA cluster on chr19q13.42 that was significantly overexpressed in all A and AB tumours and
whose expression was virtually absent in the other thymomas and normal tissues. Overexpression of this microRNA cluster
activates the PI3K/AKT/mTOR pathway. Treatment of a thymoma AB cell line with a panel of PI3K/AKT/mTOR inhibitors resulted in
marked reduction of cell viability.
Conclusions: A large microRNA cluster on chr19q13.42 is a transcriptional hallmark of type A and AB thymomas. Furthermore,
this cluster activates the PI3K pathway, suggesting the possible exploration of PI3K inhibitors in patients with these subtypes
of tumour. This work has led to the initiation of a phase II clinical trial of PI3K inhibition in relapsed or refractory thymomas
(http://clinicaltrials.gov/ct2/show/NCT02220855).
Thymoma is a rare disease with B400 cases diagnosed in the
United States per year (Engels, 2010). Though considered by some
to be benign, all subtypes of thymoma have been reported to be
invasive and capable of metastasis (Jain et al, 2010; Vladislav et al,
2012). Although untreated thymomas are uniquely sensitive to
chemotherapy, standard chemotherapy alone is not curative.
Surgical management is highly beneficial for those with resectable
disease, but 10–29% will recur after initial therapy (Hamaji et al,
2014). Thymomas are histologically characterised into several
World Health Organisation (WHO) subtypes based on epithelial
cell morphology and lymphocytic infiltration. These include the A
and AB subtypes defined by spindle/oval epithelial cell morphology
(AB includes dense lymphocytic foci); B1 that has a round
epithelioid shape with a predominance of lymphocytes; B2 that has
a polygonal shape with lymphocytic infiltration; B3 that is defined
by cells with a round or polygonal epithelioid shape and a small
lymphocytic component; and C that is defined as thymic
carcinoma with histological features common of epithelial cancers
(Dadmanesh et al, 2001; Travis et al, 2004). Though generally
accepted, this classification has its detractors based on complexity,
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interobserver inconsistency, sampling errors (in which multiple
subtypes are seen in larger specimens), and lack of prognostic
consistency (Moran and Suster, 2008; Wick, 2008, 2010; Zucali
et al, 2013). Furthermore, patients with advanced thymoma are
typically treated with systemic therapy, independent of histologic
classification. Published molecular data to date have been unable
to identify recurrent DNA mutations or somatic copy number
alterations that have correlated with histologic subtype or
clinicopathologic features, but have revealed molecular distinctions
between thymoma and thymic carcinoma, suggesting that
thymomas are a separate entity from thymic carcinomas (Girard
et al, 2009). Little is known about the biology of these rare
thymoma tumours, in particular, the extent of dysregulation
present in the transcriptional landscape. To examine this land-
scape, next-generation RNA sequencing (RNA-seq) was performed
to profile the entire transcriptome of these tumours. Because of the
comprehensive nature of this technology, measurement of the gene
expression of all protein coding as well as noncoding RNAs, in
particular precursor microRNAs, was completed. These data were
then analysed to determine whether novel biological hallmarks
could lend clues to biomarkers and potential treatments for this
disease.
MATERIALS AND METHODS
Samples and RNA-sequencing. Frozen tissue from 13 thymic
malignancies and 3 normal tissues used for RNA-seq were obtained
from the Indiana University Simon Cancer Center Tissue Bank.
Samples were WHO subtyped by an experienced pathologist (SB) in
a blinded manner. Because thymic malignancies can have a pervasive
lymphocytic presence, we chose tumour tissues that were lympho-
cyte poor and contained high tumour cellularity in order to enrich
for tumour-specific RNA. The WHO subtypes represented include:
(4) type A, (2) AB, (1) B2, (5) B3, (1) C, and (3) normal tissues
(sample details in Supplementary Table 1). RNA was extracted using
the Ambion Ribopure extraction kit (Life Technologies, South San
Francisco, CA, USA) followed by ribosomal depletion using the
Ribominus Eukaryote Kit (Life Technologies). The RNA-seq libraries
were prepared using the Total RNA-Seq Kit (Life Technologies).
Emulsion PCR and bead preparation was conducted according to
the manufacturer’s instructions. Each library was barcoded to allow
multiple samples to be sequenced simultaneously. The 16 cDNA
libraries were sequenced on a Life Technologies SOLiD 3-plus
and SOLiD 4 sequencers using two 50 bp fragment runs and
one 75 35 bp paired-end run (Alignment information in
Supplementary Table 2). For gene expression, mapping of reads to
the genome (hg19) was performed using the Life Technologies
LifeScope 2.5.1 pipeline and output BAM (Binary Alignment/
Mapping) files imported into Partek Genomics Suite for analysis.
BAM files to be submitted to the NCBI Gene Expression Omnibus
(GEO) for public availability. In Partek, mapped reads were cross-
referenced against known genes from the RefSeq database followed
by statistical comparison of RPKM (reads per kilobase of exon per
million mapped reads) values for each gene. In addition, mapped
reads were also cross-referenced against a database of precursor
microRNAs downloaded from miRBase version 20 (ftp://mirba-
se.org/pub/mirbase/CURRENT/genomes/hsa.gff3) (Kozomara and
Griffiths-Jones, 2014). Unsupervised hierarchical clustering analyses
using Spearman’s correlation with average linkage were performed
using Partek and network analyses were performed using Ingenuity
Pathway Analysis (Ingenuity Systems, Redwood City, CA, USA).
Validation sample set and qPCR. For miRNA validation, a larger
independent set of 35 thymic malignancies was used. RNA was
extracted from these tissues using the All Prep RNA/DNA/Protein
kit with an additional miRNA enrichment step as per the
manufacturer’s protocol (Qiagen, Valencia, CA, USA). Samples
were reverse transcribed using the microRNA Reverse Transcrip-
tion Kit (Life Technologies). Validation of miRNA expression was
performed by qPCR using a custom miRNA TaqMan low-density
array with the Life Technologies 7900HT Real-Time PCR System.
RNU24, RNU44, and RNU48 were used as housekeeper genes. The
qPCR data were analysed using the SDS2.3 and DataAssist v3.01
software from Life Technologies. All studies on all samples were
approved by the IU Institutional Review Board.
Protein analyses. Protein measurements in thymoma tissues for
PTEN and phospho-AKT (p-Ser 473) were performed using
enzyme-linked immunosorbent assays (ELISA) (R&D Systems,
Minneapolis, MN, USA). Statistical analyses were performed using
Prism 6.0 software (GraphPad Software, La Jolla, CA, USA) with
Student’s two-sided two-sample t-test. For cell-based experiments,
we used a previously described thymoma AB cell line (IU-TAB1)
developed at Indiana University (Indianapolis, IN, USA;
Gokmen-Polar et al, 2012). Protein analysis of IU-TAB1 cells before
and after transfection with human mir-517a and mir-519d (Ambion,
Austin, TX, USA) was executed using western blot. Cells
(n¼ 300 000) were seeded in 6-well plates and transfected with the
microRNAs individually and in combination for 60 h. Protein was
isolated and quantified using RIPA buffer and BCA assay (Pierce,
Rockford, IL, USA). The protein lysate (20mg) was run on a precast
10% Bis-Tris gel (Life Technologies) and wet transferred to a PVDF
membrane. After blocking, membranes were probed with PTEN,
phospho-AKT (Ser 473), AKT (pan-AKT1/2/3), phospho-mTOR
(Ser 2448), mTOR, phospho-p70 S6K (Ser 371), phospho-4E-BP1
(Thr 37/46), and b-actin (Cell Signaling Technology, Danvers, MA,
USA) antibodies. Detection was performed using SuperSignal West
Pico Chemiluminescent Substrate (Pierce) and imaging was performed
on a Fujifilm LAS 4000 imager (Fujifilm, Valhalla, NY, USA).
Drug sensitivity experiments. IU-TAB1 cells (n¼ 10 000) were
seeded in 96-well plates and dosed with increasing concentrations of
PI3K and PI3K/mTOR inhibitors. Measurement of cell viability was
performed using the Promega CellFlour assay (Madison, WI, USA)
using a Bio-Tek (Winooski, VT, USA) Synergy 4 multi-function
plate reader. All experiments were performed with triplicate technical
replicates, and each experiment performed three times. The IC50
values were calculated using Prism 6.0 software.
RESULTS
RNA-seq of protein coding genes confirms WHO histological
subtypes. In our first analysis, we performed unsupervised hierarch-
ical clustering using all expressed protein coding genes in these samples.
As seen in Figure 1A, the dendrogram demonstrates a separation of
samples based on gene expression in 100% concordance with theWHO
histological subtype. In particular, the A and AB samples separate from
the B3 samples. The lymphocyte-rich B2/B3 sample separates from the
A, AB, and B3 samples and is concordant with the lymphocyte-rich
normal thymus tissues. The lone C sample (which is histologically
defined as a thymic carcinoma, not thymoma) also separates into its
own cluster. These data demonstrate that the WHO histological
subtypes mirror the underlying transcriptional differences. We then
compared the gene expression values of the A and AB samples vs the
other samples and observed that many of the most significant
differentially expressed genes were pre-miRNAs all coming from a
single cluster on chromosome 19q13.42 (Supplementary Table 3).
Precursor miRNA analysis defines subtypes and identifies
overexpressed cluster. Because the RefSeq database is not a
comprehensive annotation of microRNAs, we then analysed the
data using a database of precursor microRNAs downloaded from
the UCSC (University of California, Santa Cruz) genome browser.
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Because standard RNA-seq chemistry only measures longer length
RNAs, we focussed the analysis on the longer precursor form with
validation of the mature form using qPCR. As seen in Figure 1B,
unsupervised hierarchical clustering of expressed pre-miRNAs
separated the samples based on WHO histological subtypes, similar
to what was seen with protein coding genes, but with the A and AB
samples mixed in a single dendrogram cluster. Differential
expression analysis again revealed many of the most significant
genes originating from a single microRNA cluster on chromosome
19q13.42 (C19MC) (Supplementary Table 4). A deeper analysis of
this cluster revealed high overexpression of these microRNA in A
and AB thymomas and virtually absent expression in the other
samples (Table 1). To validate this observation, we performed
qPCR for the miRNA cluster in a separate set of 35 thymic
malignancies. The qPCR assays were designed for the mature
version of the miRNAs. As seen in Figure 2, qPCR demonstrated a
strong separation of our samples into two groups based on miRNA
expression. All A and AB samples were classified into the group
positive for C19MC cluster, whereas the B1, B2, and B3 samples
were present in the C19MC-negative group. Of note, only one
discordant sample was present, a B1 thymoma, and it was classified
into the C19MC cluster-positive group.
C19MC modulation of the PI3K/AKT pathway. Previous work
in hepatocellular carcinoma has demonstrated that the C19MC
cluster causes activation of the PI3K/AKT pathway by inhibition of
the PI3K antagonist PTEN, and also of the cell cycle inhibitor p21
(Fornari et al, 2012). To investigate this, we performed a pathway
analysis of the PI3K/AKT pathway and overlaid genes that were
differentially expressed between A and AB vs B3 thymomas (false
discovery rate (FDR) o25%). As seen in Figure 3A, PI3K was
significantly overexpressed in A and AB thymomas along with
PREX2 (a PTEN antagonist; Fine et al, 2009), Ras, and MAGI. In
addition, there was significant downregulation of the FOXO family
of transcription factors, well known to be inactivated when PI3K/
AKT is activated (Brunet et al, 1999), along with BIM, p21cip1, and
MAST2. To validate the pathway analysis, we performed protein
measurements for phospho-AKT (Ser 473) and PTEN by ELISA on
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Figure 1. Hierarchical clustering of thymoma samples. (A) Unsupervised hierarchical clustering of all expressed RefSeq genes in the thymoma and
normal samples by RNA-Seq. Clustering was performed using RPKM values of expressed genes. The dendrogram demonstrates separation of the
samples based on gene expression that is completely concordant with the WHO histological subtype (LR¼ lymphocyte rich). Red indicates higher
expression and blue indicates lower expression. (B) Unsupervised hierarchical clustering of all expressed precursor microRNAs (as defined by the
UCSC genome browser) in the thymoma and normal samples. The dendogram demonstrates a mixing of the A and AB thymomas with separation
of the other subtypes.
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the same 35 thymomas used in the previous miRNA qPCR
validation (Figure 3B). In congruence with the pathway analysis,
we observed significantly higher activated phospho-AKT in the
C19MC-positive thymomas as compared with the C19MC-
negative tumours (Po0.0001) as well as the expected down-
regulation of PTEN in the C19MC-positive thymomas as
compared with the C19MC-negative tumours (Po0.0001).
To provide additional support that the C19MC cluster induces
activation of the PI3K pathway, we performed an in vitro
experiment using the only known existing human Thymoma AB
cell line, IU-TAB1. IU-TAB1 is a well-characterised cell line of AB
thymoma origin, though expression of the C19MC cluster is low.
Two C19MC miRNAs (mir-519d and mir-517a) were transfected
into the IU-TAB1 cell line. These two miRNAs are known or
predicted regulators of PTEN, respectively (Fornari et al, 2012;
Kozomara and Griffiths-Jones, 2014). Thymoma cells were
transfected with the microRNAs individually as well as in
combination. As seen in Figure 4, the transfection of the
combination of mir-517a and mir-519d decreased protein expres-
sion of PTEN along with a corresponding increase in p-AKT and
p-70 S6K. Upregulation of p-AKT, p-MTOR, p-70 S6K, and p-4E-
BP1 was also observed with mir-517a alone.
Sensitivity to PI3K pathway inhibitors. To demonstrate potential
sensitivity of thymomas to PI3K pathway inhibitors, IU-TAB1 cells
were dosed with increasing concentrations of 8 different PI3K or
dual PI3K/mTOR inhibitors that have been previously tested in
phase 2 or phase 3 clinical trials. As seen in Figure 5, we observe
significant sensitivity of this cell line to these inhibitors, with PF-
04691502 and BEZ235 demonstrating the best reduction in cell
viability at an IC50 of 118 and 210 nM, respectively. Both of these
drugs are dual PI3K/mTOR inhibitors, and this may explain their
increased potency compared with the other inhibitors tested.
DISCUSSION
Herein, we demonstrate that a large microRNA cluster on
chromosome 19q13.42 (C19MC) is a genomic hallmark of type
A and AB thymomas. This cluster is known to be the largest
microRNA cluster in the human genome whose presence is
restricted to primates (Zhang et al, 2008; Flor and Bullerdiek,
2012). This cluster is normally expressed only in embryonic
development and is normally silent in adult tissues except the
Table 1. Median RPKM expression of precursor microRNAs in the C19MC cluster grouped by WHO subtype
Precursor miRNA Chromosome Start End A AB B2/B3 B3 C Normal
hsa-mir-498 Chr19 54177451 54177575 2.46 0.88 0.00 0.00 0.00 0.00
hsa-mir-512-1 Chr19 54169933 54170017 10.25 9.58 0.00 0.00 0.25 0.00
hsa-mir-515-1 Chr19 54182257 54182340 5.50 5.07 0.00 0.00 0.00 0.00
hsa-mir-516a-1 Chr19 54259995 54260085 0.50 0.29 0.00 0.00 0.00 0.00
hsa-mir-516b-1 Chr19 54240099 54240189 2.20 2.30 0.00 0.00 0.00 0.00
hsa-mir-516b-2 Chr19 54228696 54228781 0.66 1.67 0.00 0.00 0.00 0.00
hsa-mir-517a Chr19 54215522 54215609 24.45 39.95 0.00 0.00 0.00 0.00
hsa-mir-517b Chr19 54224330 54224397 0.52 0.33 0.00 0.00 0.00 0.00
hsa-mir-517c Chr19 54244567 54244662 2.52 2.27 0.00 0.00 0.00 0.00
hsa-mir-518a-1 Chr19 54234260 54234345 0.33 0.67 0.00 0.00 0.00 0.00
hsa-mir-518b Chr19 54205991 54206074 14.04 8.72 0.36 0.00 0.00 0.00
hsa-mir-518c Chr19 54211989 54212090 0.34 0.47 0.00 0.00 0.00 0.17
hsa-mir-518e Chr19 54233092 54233180 5.78 5.20 0.00 0.00 0.00 0.00
hsa-mir-518f Chr19 54203269 54203356 0.36 0.00 0.00 0.00 0.00 0.00
hsa-mir-519a-1 Chr19 54255651 54255736 3.87 6.21 0.00 0.00 0.00 0.00
hsa-mir-519b Chr19 54198467 54198548 0.69 0.00 0.00 0.00 0.00 0.00
hsa-mir-519c Chr19 54189723 54189810 0.66 0.13 0.00 0.00 0.00 0.00
hsa-mir-519d Chr19 54216601 54216689 14.32 9.49 0.00 0.00 0.00 0.19
hsa-mir-520b Chr19 54204481 54204542 0.50 0.50 0.00 0.00 0.00 0.00
hsa-mir-520d Chr19 54223350 54223437 1.00 0.65 0.00 0.00 0.00 0.00
hsa-mir-520f Chr19 54185413 54185500 0.94 0.35 0.00 0.00 0.00 0.00
hsa-mir-520g Chr19 54225420 54225510 6.70 6.49 0.00 0.00 0.00 0.00
hsa-mir-520h Chr19 54245766 54245854 1.61 1.56 0.00 0.00 0.00 0.00
hsa-mir-521-2 Chr19 54219848 54219935 1.36 1.18 0.00 0.00 0.00 0.00
hsa-mir-522 Chr19 54254465 54254552 1.17 0.83 0.00 0.00 0.00 0.00
hsa-mir-523 Chr19 54201639 54201726 1.25 0.78 0.00 0.00 0.00 0.00
hsa-mir-524 Chr19 54214256 54214343 0.38 0.18 0.00 0.00 0.00 0.00
hsa-mir-525 Chr19 54200787 54200872 5.59 3.13 0.00 0.00 0.00 0.00
hsa-mir-526a-1 Chr19 54209506 54209591 0.12 0.31 0.00 0.00 0.00 0.00
hsa-mir-526b Chr19 54197647 54197730 2.62 2.05 0.00 0.00 0.00 0.00
hsa-mir-1323 Chr19 54175222 54175294 3.94 1.08 0.00 0.00 0.00 0.00
Abbreviations: Chr¼ chromosome; miRNA¼microRNA; RPKM¼ reads per kilobase per million; WHO¼World Health Organisation. Genomic coordinates are from human genome version 19
(hg19).
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placenta (Zhang et al, 2008; Bullerdiek and Flor, 2012). A search
for other cancers revealed other tumour types that overexpress this
cluster. Of interest, ETANTRs (embryonal tumours with abundant
neuropil and true rosettes), a rare and highly aggressive primitive
neuroendocrine tumour, overexpress this cluster in 93% of cases
(Korshunov et al, 2010). In ETANTRs, overexpression of this
cluster is mediated via somatic gene amplification (Korshunov
et al, 2010). In a similarly classified set of tumours, ETMRs
(embryonal tumours with multilayered rosettes), 12 out of 12
ETMRs demonstrated overexpression of C19MC driven by a fusion
of the TTYH1 gene promoter (tweety family member 1) with
C19MC, suggesting that a translocation along with amplification
drives expression in these rare tumours (Kleinman et al, 2014).
Overexpression of this cluster is similarly seen in thyroid
adenomas (Rippe et al, 2010), parathyroid adenomas (Vaira et al,
2012), hepatic mesenchymal hamartomas (Kapur et al, 2014),
hepatocellular carcinomas (Fornari et al, 2012), and in a subset of
tamoxifen-resistant breast cancers (Kapur et al, 2014), mediated by
a variety of mechanisms including gene amplification, chromoso-
mal translocations, and hypomethylation. The mechanism of
overexpression of this cluster in thymoma is currently unknown,
but data from The Cancer Genome Atlas (TCGA) thymoma
project will hopefully shed light onto the mechanism when the data
become available. Of further interest to thymoma, it has been
recently hypothesised that C19MC exosomes are potent immuno-
modulators that may suppress immune function in the tumour
microenvironment (Bullerdiek and Flor, 2012). Given the pre-
valence of autoimmune diseases in patients with thymoma
(myasthenia gravis, red cell aplasia, Good’s syndrome, and others;
Shelly et al, 2011), a link between C19MC and autoimmunity is
worth further exploration.
One of the key functions of this microRNA cluster is the
overactivation of the PI3K/AKT pathway (Fornari et al, 2012).
Although overactivation of this pathway is common in many
cancers, the mean of activation varies, but in many cases is
achieved via somatic mutations in PIK3CA or PTEN. This does not
seem to be the case for thymoma where previous work has
demonstrated a lack of mutations in these genes (Girard et al,
2009). To confirm overactivation, pathway analysis demonstrated
differentially expressed genes consistent with an activated PI3K/
AKT pathway in our type A and AB thymomas. Further protein-
level data in our validation cohort demonstrated elevated p-AKT
and decreased PTEN in our C19MC-positive tumours. To translate
these findings, we used an established thymoma AB cell line
(Gokmen-Polar et al, 2012) and tested a variety of PI3K and dual
PI3K/mTOR inhibitors that have been tested in cancer clinical
trials. Recently, PI3K and dual PI3K inhibitors have
shown promise as potential clinical agents (Rodon et al, 2013).
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Figure 2. Validation of expression of the C19MC cluster by qPCR in an independent sample set of 35 thymomas. Expression data demonstrate a
separation of the samples into two distinct groups. All A and AB samples were in the C19MC-positive group, whereas the B1, B2, and B3 samples
were in the C19MC-negative group, except for one discordant B1 sample in the C19MC-positive group. Two-digit numbers after the WHO
subtype below the map are the sample numbers (from Supplementary Table 1). Six-digit values on the right side of the heatmap after the
microRNA gene symbol represent the miRNA qPCR assay IDs from Life Technologies.
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In our cell-based in vitro studies we demonstrate a significant
inhibition of cell viability using these agents with our best IC50
approaching 100 nM. Although the majority of type A and AB
thymomas have a relatively benign course (Okuma et al, 2014),
treated effectively with surgery, a portion can metastasise,
primarily to the pleura (Vladislav et al, 2012). Our data suggest
that a clinical trial of PI3K inhibitors is well warranted for this
patient population with a phase II trial recently initiated
in relapsed or refractory thymomas (http://clinicaltrials.gov/ct2/
show/NCT02220855).
Finally, significant controversy exists around the histological
subtyping of thymomas with significant discordance among
pathologists (Suster and Moran, 2006; Zucali et al, 2013). Our
data demonstrate that the underlying gene expression of these
tumours is 100% concordant with histological subtyping by an
experienced pathologist who specialises in thymoma (SS Badve).
Such expertise is not readily available at many institutions and thus
a molecular classification may be useful to increase homogeneity
across institutions. This is important for a rare disease, where
much of the prognostic data are derived in cumulative from
various cancer centres. Because C19MC expression is largely
restricted to type A and AB thymomas, measurement of this
microRNA cluster as a routine molecular diagnostic in thymoma
tissues may be well warranted and potentially superior to
histological subtyping by microscopy. As future studies to
characterise potential subtype-specific targets, like PI3K, are
elucidated, accurate clinical diagnostics of WHO subtype will be
essential for a precision medicine approach in this disease. In
conclusion, we demonstrate that overexpression of the largest
miRNA cluster in the human genome on chromosome 19q13.42 is
a transcriptional hallmark of type A and AB thymomas, and
treatment of these tumours with PI3K pathway inhibitors may be
an effective novel therapy. Outcomes from our clinical trial, as well
as studies of the C19MC cluster with PI3K pathway inhibitors in
other cancer types, will help to shed light on the utility of C19MC
as a therapeutic biomarker.
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Figure 3. PI3K pathway analysis among thymoma subtypes. (A) Network analysis demonstrates overexpressed and underexpressed genes in A
and AB thymomas vs B3 thymomas (FDR o25%) that would be expected of an overactivated PI3K/AKT pathway. Red indicates upregulated
expression in A and AB thymomas and green indicates downregulated expression in A and AB thymomas. (B) Protein ELISA for activated phospho-
AKT (Ser 473), and PTEN in a validation set of 35 thymomas and 3 normal tissues.
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